Business in the Burbs

Curemark to begin tests of drug in autism victims

March

Curemark LLC, a Rye-based drug research and development company focused on neurological diseases, said that it has received regulatory clearance to start a drug testing program.

The tests, designed to study the effectiveness of Curemark’s CM-AT medication as an autism treatment, are expected to begin the tests at multiple sites across the country during the second quarter. “With 1 in 150 children diagnosed with autism, we have children who are suffering,” Dr. Joan Fallon, Curemark’s chief executive officer, said in a written statement. “We are very excited about the opportunity to enter a Phase III trial for this ever-growing population of children.”

This entry was posted on Wednesday, March 25th, 2009 at 3:46 pm by Jay Loomis. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Biopharmaceutical

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.